Loading...
Market
What will be the market cap of Recursion Pharmaceuticals by December 31, 2025?
3
Resolution / Starting Odds
Below $2 billion • 25%
$2 billion to $4 billion • 25%
$4 billion to $6 billion • 25%
Above $6 billion • 25%
Stock market data from financial news websites or stock exchange records
Story
Recursion's AI-Derived REC-1245 Gets FDA Clearance; First-in-Class RBM39 Degrader for Solid Tumors, Lymphoma
Oct 2, 2024, 12:20 PM
Recursion Pharmaceuticals (RXRX) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader intended for biomarker-enriched solid tumors and lymphoma. This marks the company's first program to combine its end-to-end suite of AI-enabled active learning modules, moving from target identification to IND enabling studies in under 18 months, more than twice as fast as industry standards. The FDA clearance paves the way for Recursion to initiate a Phase I/II clinical trial of REC-1245.
View original story
Similar markets
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Increase by 10% or more • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant increase • 25%
Below $10 • 25%
$10 to $15 • 25%
$15 to $20 • 25%
Above $20 • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Increase by more than 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Partnership with a major pharmaceutical company • 25%
Acquisition by a major pharmaceutical company • 25%
Partnership with a tech company • 25%
No partnership or acquisition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%